Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci. 2020;21(11):4012.

CAS  PubMed  PubMed Central  Google Scholar 

Yang L, Ying X, Liu S, Lyu G, Xu Z, Zhang X, et al. Gastric cancer: epidemiology, risk factors and prevention strategies. Chin J Cancer Res. 2020;32(6):695–704.

CAS  PubMed  PubMed Central  Google Scholar 

Chen Z, Li Y, Tan B, Zhao Q, Fan L, Li F, et al. Progress and current status of molecule-targeted therapy and drug resistance in gastric cancer. Drugs Today. 2020;56(7):469–82.

CAS  Google Scholar 

Li Z, Liu ZM, Xu BH. A meta-analysis of the effect of microRNA-34a on the progression and prognosis of gastric cancer. Eur Rev Med Pharmacol Sci. 2018;22(23):8281–7.

CAS  PubMed  Google Scholar 

Gong LG, Shi JC, Shang J, Hao JG, Du X. Effect of miR-34a on resistance to sunitinib in breast cancer by regulating the Wnt/beta-catenin signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(3):1151–7.

PubMed  Google Scholar 

Chen NN, Zhou KF, Miao Z, Chen YX, Cui JX, Su SW. Exosomes regulate doxorubicin resistance in breast cancer via miR-34a-5p/NOTCH1. Mol Cell Probes. 2024;76: 101964.

CAS  PubMed  Google Scholar 

Weng YS, Tseng HY, Chen YA, Shen PC, Al Haq AT, Chen LM, et al. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer. Mol Cancer. 2019;18(1):42.

PubMed  PubMed Central  Google Scholar 

Yang Y, Yuan H, Zhao L, Guo S, Hu S, Tian M, et al. Targeting the miR-34a/LRPPRC/MDR1 axis collapse the chemoresistance in P53 inactive colorectal cancer. Cell Death Differ. 2022;29(11):2177–89.

CAS  PubMed  PubMed Central  Google Scholar 

Zuo Y, Zheng W, Liu J, Tang Q, Wang SS, Yang XS. MiR-34a-5p/PD-L1 axis regulates cisplatin chemoresistance of ovarian cancer cells. Neoplasma. 2020;67(1):93–101.

CAS  PubMed  Google Scholar 

Deng XJ, Zheng HL, Ke XQ, Deng M, Ma ZZ, Zhu Y, et al. Hsa-miR-34a-5p reverses multidrug resistance in gastric cancer cells by targeting the 3’-UTR of SIRT1 and inhibiting its expression. Cell Signal. 2021;84: 110016.

CAS  PubMed  Google Scholar 

Azimi M, Totonchi M, Ebrahimi M. Determining the role of microRNAs in self-renewal, metastasis and resistance to drugs in human gastric cancer based on data mining approaches: a systematic review. Cell J. 2022;24(1):1–6.

PubMed  PubMed Central  Google Scholar 

Lengrand J, Pastushenko I, Vanuytven S, Song Y, Venet D, Sarate RM, et al. Pharmacological targeting of netrin-1 inhibits EMT in cancer. Nature. 2023;620(7973):402–8.

CAS  PubMed  PubMed Central  Google Scholar 

Ducarouge B, Redavid AR, Victoor C, Chira R, Fonseca A, Hervieu M, et al. Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor. Cell Death Differ. 2023;30(10):2201–12.

CAS  PubMed  PubMed Central  Google Scholar 

Cassier PA, Navaridas R, Bellina M, Rama N, Ducarouge B, Hernandez-Vargas H, et al. Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer. Nature. 2023;620(7973):409–16.

CAS  PubMed  PubMed Central  Google Scholar 

Bellina M, Bernet A. Netrin-1, a novel antitumoral target. Med Sci (Paris). 2022;38(4):351–8.

PubMed  Google Scholar 

Liu J, Bi J, Li Z, Li Z, Liu X, Kong C. miR-214 reduces cisplatin resistance by targeting netrin-1 in bladder cancer cells. Int J Mol Med. 2018;41(3):1765–73.

CAS  PubMed  Google Scholar 

Li Y, Xia Y, Jiang T, Chen Z, Shen Y, Lin J, et al. Long noncoding RNA DIAPH2-AS1 promotes neural invasion of gastric cancer via stabilizing NSUN2 to enhance the m5C modification of NTN1. Cell Death Dis. 2023;14(4):260.

CAS  PubMed  PubMed Central  Google Scholar 

Yin K, Wang L, Zhang X, He Z, Xia Y, Xu J, et al. Netrin-1 promotes gastric cancer cell proliferation and invasion via the receptor neogenin through PI3K/AKT signaling pathway. Oncotarget. 2017;8(31):51177–89.

PubMed  PubMed Central  Google Scholar 

Yin K, Shang M, Dang S, Wang L, Xia Y, Cui L, et al. Netrin-1 induces the proliferation of gastric cancer cells via the ERK/MAPK signaling pathway and FAK activation. Oncol Rep. 2018;40(4):2325–33.

CAS  PubMed  Google Scholar 

Barbosa R, Acevedo LA, Marmorstein R. The MEK/ERK network as a therapeutic target in human cancer. Mol Cancer Res. 2021;19(3):361–74.

CAS  PubMed  Google Scholar 

Zou F, Rao T, Chen W, Song T, Li T, Hu W, et al. DUSP2 affects bladder cancer prognosis by down-regulating MEK/ERK and P38 MAPK signaling pathways through PTPN7. Cell Signal. 2023;112: 110893.

CAS  PubMed  Google Scholar 

Liu O, Wang C, Wang S, Hu Y, Gou R, Dong H, et al. Keratin 80 regulated by miR-206/ETS1 promotes tumor progression via the MEK/ERK pathway in ovarian cancer. J Cancer. 2021;12(22):6835–50.

CAS  PubMed  PubMed Central  Google Scholar 

Huang W, Hu X, He X, Pan D, Huang Z, Gu Z, et al. TRIM29 facilitates gemcitabine resistance via MEK/ERK pathway and is modulated by circRPS29/miR-770-5p axis in PDAC. Drug Resist Updat. 2024;74: 101079.

CAS  PubMed  Google Scholar 

Zhang JX, Xu Y, Gao Y, Chen C, Zheng ZS, Yun M, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017;16(1):18.

PubMed  PubMed Central  Google Scholar 

Xu F, Wang Y, Ling Y, Zhou C, Wang H, Teschendorff AE, et al. dbDEMC 3.0: functional exploration of differentially expressed miRNAs in cancers of human and model organisms. Genom Proteomics Bioinf. 2022;20(3):446–54.

Google Scholar 

Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5(3): 100625.

CAS  PubMed  PubMed Central  Google Scholar 

Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020;48(W1):W509–14.

CAS  PubMed  PubMed Central  Google Scholar 

Yu ZH, Chen ZH, Zhou GL, Zhou XJ, Ma HY, Yu Y, et al. miR-92a-3p promotes breast cancer proliferation by regulating the KLF2/BIRC5 axis. Thorac Cancer. 2022;13(21):2992–3000.

CAS  PubMed  PubMed Central  Google Scholar 

Hashemi M, Arani HZ, Orouei S, Fallah S, Ghorbani A, Khaledabadi M, et al. EMT mechanism in breast cancer metastasis and drug resistance: revisiting molecular interactions and biological functions. Biomed Pharmacother. 2022;155: 113774.

CAS  PubMed  Google Scholar 

Zuo J, Wen M, Li S, Lv X, Wang L, Ai X, et al. Overexpression of CXCR4 promotes invasion and migration of non-small cell lung cancer via EGFR and MMP-9. Oncol Lett. 2017;14(6):7513–21.

PubMed  PubMed Central  Google Scholar 

Degirmenci U, Wang M, Hu J. Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. 2020;9(1):198.

CAS  PubMed  PubMed Central  Google Scholar 

Zhao N, Guo Y, Liu P, Chen Y, Wang Y. Sirtuin 2 promotes cell stemness and MEK/ERK signaling pathway while reduces chemosensitivity in endometrial cancer. Arch Gynecol Obstet. 2022;305(3):693–701.

CAS  PubMed  Google Scholar 

Chappell WH, Candido S, Abrams SL, Akula SM, Steelman LS, Martelli AM, et al. Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. Aging. 2020;12(11):10194–210.

CAS  PubMed  PubMed Central  Google Scholar 

Choi SJ, Jung SW, Huh S, Chung YS, Cho H, Kang H. Alteration of DNA methylation in gastric cancer with chemotherapy. J Microbiol Biotechnol. 2017;27(8):1367–78.

CAS  PubMed  Google Scholar 

Kousar K, Ahmad T, Abduh MS, Kanwal B, Shah SS, Naseer F, et al. miRNAs in regulation of tumor microenvironment, chemotherapy resistance, immunotherapy modulation and miRNA therapeutics in cancer. Int J Mol Sci. 2022;23(22):13822.

CAS  PubMed  PubMed Central  Google Scholar 

He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, et al. miRNA-based biomarkers, therapies, and resistance in Cancer. Int J Biol Sci. 2020;16(14):2628–47.